All News

GCA,woman

Secukinumab Use in Refractory Giant Cell Arteritis

Jack Cush, MD

In 2023, the phase 2 TitAIN study showed that the effectiveness and safety of secukinumab in 52 patients with giant cell arteritis (GCA) who had an inadequate response to tocilizumab.

Read Article
early.ra_.2.jpg

2025 EULAR/ACR Risk Stratification Criteria for At-Risk Arthralgia

Jack Cush, MD

A collaborative EULAR/ACR expert panel has established criteria for arthralgia patients at risk (clinically suspect arthralgia) to progress to chronic rheumatoid arthritis (RA).

Read Article
RheumNow Podcast square

MTX Fails Knee OA (6.6.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com

Read Article
RA ILD RTX lung

Psoriatic Arthritis at Risk for Interstitial Lung Disease

Jack Cush, MD

A TriNetX EHR study shows that psoriatic arthritis, but not psoriasis, patients are at increased risk for interstitial lung disease (ILD).

Read Article
hudsonpsoriasis.jpg

Should You Add MTX to a TNF Inhibitor in Psoriasis?

Jack Cush, MD

Target emulation trial shows adding methotrexate (MTX) to adalimumab (ADA) does not augment the effectiveness and persistence of adalimumab alone in treating plaque psoriasis in adults. 

Read Article
autoimmune.disease

Autoimmunity Rising in Expectant Mothers

Jack Cush, MD

Lancet Rheumatology has published a UK study showing a significant increased in the number of expectant mothers beginning their pregnancies with autoimmune conditions.

Read Article
knee.oa_.jpg (keep)

Methotrexate Fails in Knee Osteoarthritis

MedPage Today

We'll be blunt: methotrexate flopped in a randomized placebo-controlled trial among patients with osteoarthritis (OA) of the knee.

Contrary to results from a previous trial in hand OA, the old-line disease-modifying anti-rheumatic drug (DMARD) failed to bring any improvement relative to placebo in either pain or an objective measure of joint inflammation after a year of treatment, according to Changhai Ding, PhD, MD, of Southern Medical University in Guangzhou, China, and colleagues.

Read Article
osteoporosis.OP_.Drugs_.jpg

Denosumab and Osteoporosis - A JAMA Review

Jack Cush, MD

An overview of denosumab use in osteoporosis (OP)  by Bauer and Ensrud was published in JAMA. 

Read Article
Kamen

Rules on Mycophenolate Use in SLE

Diane Kamen, MD, MSCR

Dr. Diane Kamen. a rheumatologist and lupologist from the Medical University of South Carolina in Charleston, South Carolina, discusses the use of mychophenolate in the management of systemic lupus. 

Read Article
52 wk Phase 3 DBRPCT of daily anakinra (100 mg sc) vs PBO in 30 giant cell arteritis pts. At wk 16 (17 ANK vs 13 PBO) there was no significant difference in relapse rates (12% vs 23%; p = 0.63). Same at wk 52 (53% vs 49% relapse). ANK didnt reduce relapses or GC exposure https://t.co/RFkkaUchsW
Dr. John Cush RheumNow ( View Tweet)
CMAJ reminds us that w/ parvovirus B19 infection, Arthropathy seen in ~60% of adolescents & adults, but the classic “slapped cheek rash” is uncommon. Symmetric, polyarticular inflamm arthralgias/itis affects PIPs, MCPS mostly. Sxs resolve w/in 3 wks. ~20% can last mos-yrs https://t.co/WXnuViSLbe
Dr. John Cush RheumNow ( View Tweet)
Rules on Mycophenolate Use in SLE Dr. Diane Kamen. a rheumatologist and lupologist from the Medical University of South Carolina in Charleston, South Carolina, discusses the use of mychophenolate in the management of systemic lupus. https://t.co/ieiUNYQbsB https://t.co/KlC0dO06tc

Links:

Dr. John Cush RheumNow ( View Tweet)
Methotrexate Fails in Knee Osteoarthritis We'll be blunt: methotrexate flopped in a randomized placebo-controlled trial among patients with osteoarthritis (OA) of the knee. https://t.co/Y9elFXTkhN https://t.co/oqDDVPGbh7

Links:

Dr. John Cush RheumNow ( View Tweet)
Review of ARF & Post-streptococcal reactive arthritis (PSRA) following Group A strept infxn. Early Dx & Rx of Strept can prevent ARF & PSRA. PSRA is a sterile arthritis, bimodal age onset, lower extrem arthritis, usually resolves without lasting sequelae https://t.co/ld208yf0Zk

Links:

Dr. John Cush RheumNow ( View Tweet)

Review of ARF & Post-streptococcal reactive arthritis (PSRA) following Group A strept infxn. Early Dx & Rx of Strept can prevent ARF & PSRA. PSRA is a sterile arthritis, bimodal age onset, lower extrem arthritis, usually resolves without lasting sequelae https://t.co/ld208yf0Zk

Links:

Dr. John Cush RheumNow ( View Tweet)

Shifting the Management Paradigm for SLE and Lupus Nephritis The paradigm for treating patients with systemic lupus erythematosus (SLE) is rapidly shifting and our patients will surely benefit with improved outcomes. https://t.co/idxMBTyTwp https://t.co/f5G3cFb3XK

Links:

Dr. John Cush RheumNow ( View Tweet)
Hydroxychloroquine: Are Your Patients Taking It? Dr. Nathalie Costedoat-Chalumeau dives into monitoring HCQ levels and what they tell us about patient adherence. 💡Learn how to spot non-compliance early. 👉 Now live on RheumNow: https://t.co/KPjyCrMTBr #LupusCare https://t.co/vRASCc9kB0

Links:

Dr. John Cush RheumNow ( View Tweet)
Using publicly available FAERS safety data, drug-induced photosensitivity (DIP) - among 17+ million safety reports, there 20,236 linked to DIP. The most common wereimmunosuppressants, monoclonal Abs, neoplastic agents, including adalimumab, adapalene, secukinumab, fingolimod https://t.co/QWg8FVvrZb
Dr. John Cush RheumNow ( View Tweet)
Contemporary lupus nephritis treatment The Lupus 2025 congress brought together world SLE thought leaders. Outcomes in lupus nephritis are akin to the glass half full. Serial monotherapy is out, as the percentage who achieved a complete renal response was very low and some https://t.co/4LVPeDn6r4
Dr. John Cush RheumNow ( View Tweet)
JAMA -- Full read review "Uveitis in Adults:" - affects adults 20 to 50 years - noninfectious anterior uveitis: corticosteroids 1st line Rx - posterior noninfectious uveitis: DMARDs 1st line Rx; Biologics 2nd line https://t.co/BJQkPtK2z2 https://t.co/9zAntZK66Q

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×